In 2018 Nobel‑winning chemist David Baker used pure computer simulation to create a hybrid cytokine drug called Neo‑2/15, a blend of IL‑2 and IL‑15. The work was published in Nature in 2019 and sparked excitement because the molecule bound its target strongly and showed therapeutic promise. However, later studies revealed serious toxicity, and by 2023 the clinical trial collapsed, wiping out huge investments and reminding the industry that safety is non‑negotiable. The story took a dramatic turn this March when Chinese academician Cao Xuetao applied advanced AI‑driven protein design to re‑engineer Neo‑2/15, eliminating its toxic side effects. Cao’s team, together with overseas collaborators, has now plugged the revamped cytokine into CAR‑NK cell therapies, reporting striking early results. The episode illustrates how AI is reshaping drug discovery: moving away from slow, brute‑force high‑throughput screens toward precise, custom‑made molecules. Yet the technology is only a tool—success still hinges on clever application and a dose of luck. Investors on both sides of the Pacific are feeling the shift. Boston‑based Lila Sciences is betting on an “AGI for science,” raising $600 million and a $2 billion valuation without a product yet. Similarly, Xaira Therapeutics has secured over $1 billion. In contrast, Chinese firms view AI as an accelerator rather than a silver bullet, emphasizing practical integration over hype.
Read moreBio Valley is a one‑stop hub for the latest discoveries, technologies, and industry trends in biopharma and life sciences. It brings together everything from metabolomics and gene therapy to nanomedicine and 3D‑printed medical devices, making complex science accessible to a broad audience. The portal highlights fresh research that could change how we treat disease. For example, a new Nature study shows that the order in which cancer‑driving genes mutate in the gut determines whether tumors grow aggressively or are kept in check, offering clues for early‑stage colorectal cancer prevention. Researchers at Nantong University uncovered how a protein called Drp1 helps nasopharyngeal cancer cells resist death and spread, pointing to potential new drug targets. At Southeast University, scientists identified the synaptic protein Neurexin as a key player in chronic pain, opening doors for better pain‑relief therapies. Tsinghua University researchers discovered that the vesicular ATP transporter VNUT limits immune responses, suggesting novel ways to boost cancer‑fighting immunity. Additional breakthroughs include a mitochondrial version of the VHL protein that reshapes cell metabolism under low‑oxygen conditions, and a kidney sensor protein (PIEZO2) that regulates fluid balance, with implications for hypertension and kidney disease. By translating these findings into clear, engaging stories, Bio Valley helps clinicians, investors, and the public stay informed about the innovations that will define tomorrow’s healthcare.
Read more